Literature DB >> 28630053

Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities.

Andrés Méndez-Lucas1, Xiaolei Li2,3, Junjie Hu2,4, Li Che2, Xinhua Song2, Jiaoyuan Jia2,5, Jingxiao Wang2, Chencheng Xie2,6, Paul C Driscoll1, Darjus F Tschaharganeh7,8, Diego F Calvisi9, Mariia Yuneva10, Xin Chen11,4.   

Abstract

Different pyruvate kinase isoforms are expressed in a tissue-specific manner, with pyruvate kinase M2 (PKM2) suggested to be the predominant isoform in proliferating cells and cancer cells. Because of differential regulation of enzymatic activities, PKM2, but not PKM1, has been thought to favor cell proliferation. However, the role of PKM2 in tumorigenesis has been recently challenged. Here we report that increased glucose catabolism through glycolysis and increased pyruvate kinase activity in c-MYC-driven liver tumors are associated with increased expression of both PKM1 and PKM2 isoforms and decreased expression of the liver-specific isoform of pyruvate kinase, PKL. Depletion of PKM2 at the time of c-MYC overexpression in murine livers did not affect c-MYC-induced tumorigenesis and resulted in liver tumor formation with decreased pyruvate kinase activity and decreased catabolism of glucose into alanine and the Krebs cycle. An increased PKM1/PKM2 ratio by ectopic PKM1 expression further decreased glucose flux into serine biosynthesis and increased flux into lactate and the Krebs cycle, resulting in reduced total levels of serine. However, these changes also did not affect c-MYC-induced liver tumor development. These results suggest that increased expression of PKM2 is not required to support c-MYC-induced tumorigenesis in the liver and that various PKM1/PKM2 ratios and pyruvate kinase activities can sustain glucose catabolism required for this process. Cancer Res; 77(16); 4355-64. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28630053      PMCID: PMC5559320          DOI: 10.1158/0008-5472.CAN-17-0498

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

Authors:  Charles Kung; Jeff Hixon; Sung Choe; Kevin Marks; Stefan Gross; Erin Murphy; Byron DeLaBarre; Giovanni Cianchetta; Shalini Sethumadhavan; Xiling Wang; Shunqi Yan; Yi Gao; Cheng Fang; Wentao Wei; Fan Jiang; Shaohui Wang; Kevin Qian; Jeff Saunders; Ed Driggers; Hin Koon Woo; Kaiko Kunii; Stuart Murray; Hua Yang; Katharine Yen; Wei Liu; Lewis C Cantley; Matthew G Vander Heiden; Shinsan M Su; Shengfang Jin; Francesco G Salituro; Lenny Dang
Journal:  Chem Biol       Date:  2012-09-21

4.  The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters.

Authors:  T Noguchi; K Yamada; H Inoue; T Matsuda; T Tanaka
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

5.  Evidence for an alternative glycolytic pathway in rapidly proliferating cells.

Authors:  Matthew G Vander Heiden; Jason W Locasale; Kenneth D Swanson; Hadar Sharfi; Greg J Heffron; Daniel Amador-Noguez; Heather R Christofk; Gerhard Wagner; Joshua D Rabinowitz; John M Asara; Lewis C Cantley
Journal:  Science       Date:  2010-09-17       Impact factor: 47.728

Review 6.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Authors:  Sybille Mazurek
Journal:  Int J Biochem Cell Biol       Date:  2010-02-13       Impact factor: 5.085

7.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

Review 8.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.

Authors:  E Eigenbrodt; M Reinacher; U Scheefers-Borchel; H Scheefers; R Friis
Journal:  Crit Rev Oncog       Date:  1992

9.  Monocytes promote liver carcinogenesis in an oncogene-specific manner.

Authors:  Vladislava Juric; Brian Ruffell; Kimberley J Evason; Junjie Hu; Li Che; Linlin Wang; Xin Chen; J Michael Bishop
Journal:  J Hepatol       Date:  2015-11-27       Impact factor: 25.083

10.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Authors:  Dimitrios Anastasiou; Yimin Yu; William J Israelsen; Jian-Kang Jiang; Matthew B Boxer; Bum Soo Hong; Wolfram Tempel; Svetoslav Dimov; Min Shen; Abhishek Jha; Hua Yang; Katherine R Mattaini; Christian M Metallo; Brian P Fiske; Kevin D Courtney; Scott Malstrom; Tahsin M Khan; Charles Kung; Amanda P Skoumbourdis; Henrike Veith; Noel Southall; Martin J Walsh; Kyle R Brimacombe; William Leister; Sophia Y Lunt; Zachary R Johnson; Katharine E Yen; Kaiko Kunii; Shawn M Davidson; Heather R Christofk; Christopher P Austin; James Inglese; Marian H Harris; John M Asara; Gregory Stephanopoulos; Francesco G Salituro; Shengfang Jin; Lenny Dang; Douglas S Auld; Hee-Won Park; Lewis C Cantley; Craig J Thomas; Matthew G Vander Heiden
Journal:  Nat Chem Biol       Date:  2012-10       Impact factor: 15.040

View more
  28 in total

Review 1.  Emerging roles of aerobic glycolysis in breast cancer.

Authors:  Z Wu; J Wu; Q Zhao; S Fu; J Jin
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

2.  The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.

Authors:  Zhong Xu; Meng Xu; Pin Liu; Shu Zhang; Runze Shang; Yu Qiao; Li Che; Silvia Ribback; Antonio Cigliano; Katja Evert; Rosa M Pascale; Frank Dombrowski; Matthias Evert; Xi Chen; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2019-06-21       Impact factor: 17.425

3.  PKM2 Is Essential for Bladder Cancer Growth and Maintenance.

Authors:  Yong Xia; Xing Wang; Yan Liu; Ellen Shapiro; Herbert Lepor; Moon-Shong Tang; Tung-Tien Sun; Xue-Ru Wu
Journal:  Cancer Res       Date:  2022-02-15       Impact factor: 13.312

4.  PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis.

Authors:  Gang Yu; Weili Sun; Yong Shen; Yongquan Hu; Henchao Liu; Weipeng Li; Yong Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

5.  miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1.

Authors:  Zhuojia Lin; Yanan Lu; Qiuyu Meng; Chen Wang; Xiaonan Li; Yuxin Yang; Xiaoru Xin; Qidi Zheng; Jie Xu; Xin Gui; Tianming Li; Hu Pu; Wujun Xiong; Jiao Li; Song Jia; Dongdong Lu
Journal:  Mol Ther Nucleic Acids       Date:  2018-04-12       Impact factor: 8.886

6.  PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect.

Authors:  Amit Gupta; Athira Ajith; Smriti Singh; Rajendra Kumar Panday; Atul Samaiya; Sanjeev Shukla
Journal:  Cell Death Dis       Date:  2018-08-01       Impact factor: 8.469

Review 7.  Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.

Authors:  Jiao Feng; Jingjing Li; Liwei Wu; Qiang Yu; Jie Ji; Jianye Wu; Weiqi Dai; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2020-07-06

8.  Identifying strategies to target the metabolic flexibility of tumours.

Authors:  Andrés Méndez-Lucas; Wei Lin; Paul C Driscoll; Nathalie Legrave; Laura Novellasdemunt; Chencheng Xie; Mark Charles; Zena Wilson; Neil P Jones; Stephen Rayport; Manuel Rodríguez-Justo; Vivian Li; James I MacRae; Nissim Hay; Xin Chen; Mariia Yuneva
Journal:  Nat Metab       Date:  2020-04-21

9.  Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.

Authors:  Haichuan Wang; Xinhua Song; Haotian Liao; Pan Wang; Yi Zhang; Li Che; Jie Zhang; Yi Zhou; Antonio Cigliano; Cindy Ament; Daphne Superville; Silvia Ribback; Melissa Reeves; Giovanni M Pes; Binyong Liang; Hong Wu; Matthias Evert; Diego F Calvisi; Yong Zeng; Xin Chen
Journal:  Hepatology       Date:  2021-06-15       Impact factor: 17.298

Review 10.  p300/CBP as a Key Nutritional Sensor for Hepatic Energy Homeostasis and Liver Fibrosis.

Authors:  Weilei Yao; Tongxin Wang; Feiruo Huang
Journal:  Biomed Res Int       Date:  2018-05-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.